Walleye Trading’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-25,604
| Closed | -$370K | – | 4138 |
|
|
2026
Q1 | $370K | Sell |
25,604
-184,974
| -88% | -$2.65M | ﹤0.01% | 2762 |
|
|
2025
Q4 | $3M | Buy |
+210,578
| New | +$2.07M | ﹤0.01% | 1632 |
|
|
2025
Q1 | – | Sell |
-511
| Closed | -$4.81K | – | 4253 |
|
|
2024
Q4 | $4.81K | Buy |
+511
| New | +$5.31K | ﹤0.01% | 4084 |
|
|
2023
Q4 | – | Sell |
-46,474
| Closed | -$528K | – | 5198 |
|
|
2023
Q3 | $565K | Buy |
+46,474
| New | +$600K | ﹤0.01% | 2850 |
|
|
2023
Q1 | – | Sell |
-21,382
| Closed | -$264K | – | 5007 |
|
|
2022
Q4 | $261K | Buy |
21,382
+14,647
| +217% | +$165K | ﹤0.01% | 3363 |
|
|
2022
Q3 | $70K | Buy |
+6,735
| New | +$75K | ﹤0.01% | 4165 |
|
|
2021
Q2 | – | Sell |
-63,096
| Closed | -$616K | – | 5281 |
|
|
2021
Q1 | $623K | Buy |
+63,096
| New | +$977K | ﹤0.01% | 2399 |
|
|
2020
Q4 | – | Sell |
-3,813
| Closed | -$78K | – | 4692 |
|
|
2020
Q3 | $54K | Sell |
3,813
-6,041
| -61% | -$88K | ﹤0.01% | 3611 |
|
|
2020
Q2 | $149K | Buy |
+9,854
| New | +$120K | ﹤0.01% | 3276 |
|
|
2019
Q2 | – | Sell |
-8,186
| Closed | -$111K | – | 4196 |
|
|
2019
Q1 | $111K | Buy |
+8,186
| New | +$100K | ﹤0.01% | 3408 |
|
Other funds holding FOLD
Walleye Trading's FOLD Position: Q2 2026 in Review
Walleye Trading sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 25,604 shares — an estimated $370K sold.
Walleye Trading first reported a position in FOLD in Q1 2019 and held it in 10 quarters. The position peaked at $3M in Q4 2025. 1 fund tracked by Wall St. Rank holds FOLD as of Q2 2026.
- Walleye Trading reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Walleye Trading sold 25,604 Amicus Therapeutics shares in Q2 2026, an estimated $370K.
- Walleye Trading first reported a position in Amicus Therapeutics in Q1 2019 and held it in 10 quarters.
- Walleye Trading's Amicus Therapeutics position peaked at $3M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.